Accès gratuit
Numéro
Med Sci (Paris)
Volume 27, Numéro 11, Novembre 2011
Page(s) 987 - 992
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20112711015
Publié en ligne 30 novembre 2011
  1. Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 2001 ; 81 : 741–766. [PubMed]
  2. Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science 2010 ; 330 : 1774. [CrossRef] [PubMed]
  3. Shibata M, Yamada S, Kumar SR, et al. Clearance of Alzheimer’s amyloid-ss(1–40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000 ; 106 : 1489–1499. [CrossRef] [PubMed]
  4. Deane R, Du Yan S, Submamaryan RK, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003 ; 9 : 907–913. [CrossRef] [PubMed]
  5. Helmer C, Pasquier F. Dartigues JF. Épidémiologie de la maladie d’Alzheimer et des syndromes apparentés Med Sci (Paris) 2006 ; 22 : 288–296. [CrossRef] [EDP Sciences] [PubMed]
  6. Cecchelli R, Berezowski V, Lundquist S, et al. Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov 2007 ; 6 : 650–661. [CrossRef] [PubMed]
  7. Candela P, Gosselet F, Miller F, et al. Physiological pathway for low-density lipoproteins across the blood-brain barrier: transcytosis through brain capillary endothelial cells in vitro. Endothelium 2008 ; 15 : 254–264. [CrossRef] [PubMed]
  8. Donahue JE, Flaherty SL, Johanson CE, et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease. Acta Neuropathol 2006 ; 112 : 405–415. [CrossRef] [PubMed]
  9. Yamada K, Hashimoto T, Yabuki C, et al. The low density lipoprotein receptor-related protein 1 mediates uptake of amyloid beta peptides in an in vitro model of the blood-brain barrier cells. J Biol Chem 2008 ; 283 : 34554–34562. [CrossRef] [PubMed]
  10. Ito S, Ohtsuki S, Terasaki T. Functional characterization of the brain-to-blood efflux clearance of human amyloid-beta peptide (1–40) across the rat blood-brain barrier. Neurosci Res 2006 ; 56 : 246–252. [CrossRef] [PubMed]
  11. Ito S, Ueno T, Ohtsuki S, et al. Lack of brain-to-blood efflux transport activity of low-density lipoprotein receptor-related protein-1 (LRP-1) for amyloid-beta peptide(1–40) in mouse: involvement of an LRP-1-independent pathway. J Neurochem 2010 ; 113 : 1356–1363. [PubMed]
  12. Pflanzner T, Janko MC, Andre-Dohmen B, et al. LRP1 mediates bidirectional transcytosis of amyloid-beta across the blood-brain barrier. Neurobiol Aging 2010 ; 12 juillet. DOI: 10.16/j.neurobiolaging.2010.05.025.
  13. Eisele YS, Obermuller U, Heilbronner G, et al. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 2010 ; 330 : 980–982. [CrossRef] [PubMed]
  14. Sutcliffe JG, Hedlund PB, Thomas EA, et al. Peripheral reduction of beta-amyloid is sufficient to reduce brain beta-amyloid: implications for Alzheimer’s disease. J Neurosci Res 2011 ; 89 : 808–814. [CrossRef] [PubMed]
  15. Jeynes B, Provias J. Evidence for altered LRP/RAGE expression in Alzheimer lesion pathogenesis. Curr Alzheimer Res 2008 ; 5 : 432–437. [CrossRef] [PubMed]
  16. Candela P, Gosselet F, Saint-Pol J, et al. Apical-to-basolateral transport of amyloid-beta peptides through blood-brain barrier cells is mediated by the receptor for advanced glycation end-products and is restricted by P-glycoprotein. J Alzheimers Dis 2010 ; 22 : 849–859. [PubMed]
  17. Sabbagh MN, Agro A, Bell J, et al. PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord 2011 ; 25 : 206–212. [CrossRef] [PubMed]
  18. Cirrito JR, Deane R, Fagan AM, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 2005 ; 115 : 3285–3290. [CrossRef] [PubMed]
  19. Vogelgesang S, Warzok RW, Cascorbi I, et al. The role of P-glycoprotein in cerebral amyloid angiopathy : implications for the early pathogenesis of Alzheimer’s disease. Curr Alzheimer Res 2004 ; 1 : 121–125. [CrossRef] [PubMed]
  20. Gao W, Eisenhauer PB, Conn K, et al. Insulin degrading enzyme is expressed in the human cerebrovascular endothelium and in cultured human cerebrovascular endothelial cells. Neurosci Lett 2004 ; 371 : 6–11. [CrossRef] [PubMed]
  21. Lynch JA, George AM, Eisenhauer PB, et al. Insulin degrading enzyme is localized predominantly at the cell surface of polarized and unpolarized human cerebrovascular endothelial cell cultures. J Neurosci Res 2006 ; 83 : 1262–1270. [CrossRef] [PubMed]
  22. Carpentier M, Robitaille Y, DesGroseillers L, et al. Declining expression of neprilysin in Alzheimer disease vasculature: possible involvement in cerebral amyloid angiopathy. J Neuropathol Exp Neurol 2002 ; 61 : 849–856. [PubMed]
  23. Gosselet F, Candela P, Sevin E, et al. Transcriptional profiles of receptors and transporters involved in brain cholesterol homeostasis at the blood-brain barrier: use of an in vitro model. Brain Res 2009 ; 1249 : 34–42. [CrossRef] [PubMed]
  24. Urmoneit B, Prikulis I, Wihl G, et al. Cerebrovascular smooth muscle cells internalize Alzheimer amyloid beta protein via a lipoprotein pathway: implications for cerebral amyloid angiopathy. Lab Invest 1997 ; 77 : 157–166. [PubMed]
  25. Bell RD, Deane R, Chow N, et al. SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat Cell Biol 2009 ; 11 : 143–153. [CrossRef] [PubMed]
  26. Bowman GL, Kaye JA, Moore M, et al. Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology 2007 ; 68 : 1809–1814. [CrossRef] [PubMed]
  27. Ujiie M, Dickstein DL, Carlow DA, et al. Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation 2003 ; 10 : 463–470. [PubMed]
  28. Tai LM, Holloway KA, Male DK, et al. Amyloid-beta-induced occludin down-regulation and increased permeability in human brain endothelial cells is mediated by MAPK activation. J Cell Mol Med 2010 ; 14 : 1101–1112. [PubMed]
  29. Marco S, Skaper SD. Amyloid beta-peptide1–42 alters tight junction protein distribution and expression in brain microvessel endothelial cells. Neurosci Lett 2006 ; 401 : 219–224. [CrossRef] [PubMed]
  30. Carrano A, Hoozemans JJ, van der Vies SM, et al. Amyloid beta Induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy. Antioxid Redox Signal 2011 ; 15 : 1167–1178. [NASA ADS] [CrossRef] [EDP Sciences] [MathSciNet] [PubMed]
  31. Hémar A, Mulle C. Maladie d’Alzheimer, peptide β-amyloïde et synapses. Med Sci (Paris) 2011 ; 27 : 733–736. [CrossRef] [EDP Sciences] [PubMed]
  32. Clavaguera F, Goedert M, Tolnay M. Induction et propagation de la pathologie par la protéine tau chez un modèle murin de la maladie d’Alzheimer. Med Sci (Paris) 2010 ; 26 : 121–124. [CrossRef] [EDP Sciences] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.